UK Markets closed

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
110.54+0.91 (+0.83%)
At close: 04:00PM EDT
106.00 -4.54 (-4.11%)
After hours: 05:18PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.21
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 3120.23
52-week low 361.28
50-day moving average 3106.35
200-day moving average 384.19

Share statistics

Avg vol (3-month) 31.12M
Avg vol (10-day) 3880.63k
Shares outstanding 587.08M
Implied shares outstanding 6N/A
Float 883.66M
% held by insiders 14.28%
% held by institutions 182.91%
Shares short (14 Jul 2022) 45.36M
Short ratio (14 Jul 2022) 45.49
Short % of float (14 Jul 2022) 46.41%
Short % of shares outstanding (14 Jul 2022) 46.13%
Shares short (prior month 14 Jun 2022) 44.98M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:6
Last split date 311 Jul 2012

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin -46.56%
Operating margin (ttm)-51.48%

Management effectiveness

Return on assets (ttm)-8.47%
Return on equity (ttm)-51.22%

Income statement

Revenue (ttm)765.79M
Revenue per share (ttm)9.20
Quarterly revenue growth (yoy)43.50%
Gross profit (ttm)-165.84M
EBITDA -354.53M
Net income avi to common (ttm)-356.56M
Diluted EPS (ttm)-7.11
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.01B
Total cash per share (mrq)23.01
Total debt (mrq)1.16B
Total debt/equity (mrq)134.82
Current ratio (mrq)5.56
Book value per share (mrq)9.60

Cash flow statement

Operating cash flow (ttm)-363.98M
Levered free cash flow (ttm)53.98M